| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-07-26 | ALK Abello (Denmark) Merck&Co (USA - NJ) | Grazax®/Grastek®, Ragwitek® and investigational house dust mite sublingual allergy immunotherapy tablets (SLIT-tablets) | grass pollen allergy, house dust mite allergy, ragweed allergy | termination of an agreement | Allergic diseases - Inflammatory diseases - Respiratory diseases | Termination of the agreement |
| 2016-07-26 | Janssen Sciences Ireland, a J&J company (USA - NJ) GSK (UK) | CNTO 7160 | asthma | licensing |
Allergic diseases - Inflammatory diseases - Respiratory diseases | Licensing agreement |
| 2016-07-26 | Kite Pharma (USA - CA) The Regents of the University of California (USA - CA) | Artificial Thymic Organoid (ATO) cell culture system | licensing | Technology - Services - Cancer - Oncology | Licensing agreement | |
| 2016-07-26 | BMS (USA - NY) Janssen Biotech, a J&J company (USA - NJ) | Opdivo® (nivolumab) and JNJ-64041757 | non-small cell lung cancer (NSCLC) | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-07-26 | Trek Therapeutics (USA - MA) Vertex Pharmaceuticals (USA - MA) | lomibuvir (VX-222) and merimepodib (VX-497) | product acquisition | Infectious diseases | Product acquisition | |
| 2016-07-25 | MDxHealth (Belgium) Cerba HealthCare Belgium | SelectMDx™ for Prostate Cancer | prostate cancer | collaboration |
Cancer - Oncology - Diagnostic | Collaboration agreement |
| 2016-07-25 | Abbvie (USA - IL) BMS (USA - NY) | Rova-T (rovalpituzumab tesirine) in combination with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) | relapsed extensive-stage small cell lung cancer (SCLC) | clinical research |
Cancer - Oncology | Clinical research agreement |
| 2016-07-21 | Boehringer Ingelheim (Germany) CZ Veterinaria (Spain) | Entericolix© vaccine | prevention of diarrhoea in piglets caused by E. coli. and C. perfringens Type C | collaboration |
Veterinary medicine | Collaboration agreement |
| 2016-07-20 | Emergent BioSolutions (USA - MD) Aptevo Therapeutics (USA - MD) | establishment of a new subsidiary in the US |
Cancer - Oncology | Establishment of a new subsidiary in the US | ||
| 2016-07-20 | Shire (UK - USA) Chronos Therapeutics (UK) | three pre-clinical development programmes targeting Central Nervous System (CNS) diseases | diseases including multiple sclerosis, addictive behaviours and potentially post-traumatic stress disorder | product acquisition |
CNS diseases - Neurological diseases - Neurodegenerative diseases | Product acquisition |
| 2016-07-20 | Aegerion Pharmaceuticals (USA - MA) | restructuring |
Rare diseases - Genetic diseases - Metabolic diseases | Restructuring | ||
| 2016-07-20 | Boehringer Ingelheim (Germany) European Stroke Organisation | The Angels Initiative | ischaemic stroke | collaboration |
Cerebrovascular diseases | Collaboration agreement |
| 2016-07-19 | 4SC (Germany) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-07-19 | Merck KGaA (Germany) | new campus in Burlington, Massachusetts | construction of new premises |
Technology - Services | Construction of new premises | |
| 2016-07-19 | Zafgen (USA - MA) | restructuring | Metabolic diseases | Restructuring | ||
| 2016-07-18 | Nascent Biotech (USA - CA) Zhejiang Hisun Pharmaceuticals (China) | pritumumab | epithelial cancers (which include brain, pancreas, colon, lung and breast) | licensing - development - commercialisation | Cancer - Oncology | Licensing agreement |
| 2016-07-14 | Pharming (The Netherlands) Swedish Orphan Biovitrum (Sweden) | Ruconest® (Rhucin® in non-European territories - conestat alfa) | acute angioedema attacks in patients with Hereditary Angioedema | licensing commercialisation distribution |
Rare diseases | Distribution agreement |
| 2016-07-14 | F-Star (UK) Christian Doppler (CD) Laboratory for Innovative Immunotherapeutics (Austria) | collaboration |
Cancer - Oncology | Collaboration agreement | ||
| 2016-07-14 | Boehringer Ingelheim (Germany) University of Dundee (UK) | medicines that target disease causing proteins for degradation (PROTACs) | R&D collaboration |
R&D agreement | ||
| 2016-07-14 | Amgen (USA - CA) Daiichi Sankyo (Japan) | nine biosimilars including biosimilars of adalimumab, bevacizumab and trastuzumab | commercialisation |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases | Commercialisation agreement |
